Johnson & Johnson (NYSE:JNJ) Shares Purchased by Adero Partners LLC

Adero Partners LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 7.7% in the third quarter, Holdings Channel reports. The firm owned 11,117 shares of the company’s stock after acquiring an additional 799 shares during the period. Adero Partners LLC’s holdings in Johnson & Johnson were worth $1,802,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Atlanta Consulting Group Advisors LLC grew its position in Johnson & Johnson by 30.5% in the third quarter. Atlanta Consulting Group Advisors LLC now owns 14,279 shares of the company’s stock valued at $2,314,000 after acquiring an additional 3,341 shares in the last quarter. Sather Financial Group Inc grew its position in Johnson & Johnson by 37.8% in the third quarter. Sather Financial Group Inc now owns 2,756 shares of the company’s stock valued at $447,000 after acquiring an additional 756 shares in the last quarter. Schear Investment Advisers LLC grew its position in Johnson & Johnson by 6.9% in the third quarter. Schear Investment Advisers LLC now owns 4,711 shares of the company’s stock valued at $763,000 after acquiring an additional 304 shares in the last quarter. Accredited Investors Inc. grew its position in Johnson & Johnson by 4.0% in the third quarter. Accredited Investors Inc. now owns 7,901 shares of the company’s stock valued at $1,280,000 after acquiring an additional 301 shares in the last quarter. Finally, Seizert Capital Partners LLC grew its position in Johnson & Johnson by 1.0% in the third quarter. Seizert Capital Partners LLC now owns 244,057 shares of the company’s stock valued at $39,552,000 after acquiring an additional 2,441 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of recent analyst reports. Morgan Stanley raised their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Guggenheim raised their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Daiwa Capital Markets downgraded shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Finally, Wells Fargo & Company raised their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $175.94.

Johnson & Johnson Stock Performance

JNJ stock opened at $154.00 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The stock has a market capitalization of $370.77 billion, a price-to-earnings ratio of 22.29, a PEG ratio of 2.74 and a beta of 0.53. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The stock’s fifty day moving average is $161.35 and its two-hundred day moving average is $156.10.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the business posted $2.66 earnings per share. On average, research analysts predict that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.22%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Insider Activity

In other news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This trade represents a 22.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.